Quantifying the chemical beauty of drugs.
暂无分享,去创建一个
G. V. Paolini | G. R. Bickerton | Jérémy Besnard | S. Muresan | A. Hopkins | J. Besnard | G. R. Bickerton | Gaia V. Paolini | Andrew L. Hopkins
[1] G. Derringer,et al. Simultaneous Optimization of Several Response Variables , 1980 .
[2] W. Todd Wipke,et al. Artificial intelligence in organic synthesis. SST: starting material selection strategies. An application of superstructure search , 1984, J. Chem. Inf. Comput. Sci..
[3] A. Ghose,et al. Atomic Physicochemical Parameters for Three‐Dimensional Structure‐Directed Quantitative Structure‐Activity Relationships I. Partition Coefficients as a Measure of Hydrophobicity , 1986 .
[4] Michael I. Jordan,et al. Advances in Neural Information Processing Systems 30 , 1995 .
[5] William T. Scherer,et al. "The desirability function: underlying assumptions and application implications" , 1998, SMC'98 Conference Proceedings. 1998 IEEE International Conference on Systems, Man, and Cybernetics (Cat. No.98CH36218).
[6] A. Ghose,et al. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. , 1999, Journal of combinatorial chemistry.
[7] C. Lipinski. Drug-like properties and the causes of poor solubility and poor permeability. , 2000, Journal of pharmacological and toxicological methods.
[8] Tudor I. Oprea,et al. Property distribution of drug-related chemical databases* , 2000, J. Comput. Aided Mol. Des..
[9] Jun Xu,et al. Drug-Like Index: A New Approach to Measure Drug-Like Compounds and Their Diversity. , 2001 .
[10] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.
[11] A. Hopkins,et al. The druggable genome , 2002, Nature Reviews Drug Discovery.
[12] Stephen R. Johnson,et al. Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.
[13] W. Pearson,et al. Current Protocols in Bioinformatics , 2002 .
[14] M. Congreve,et al. A 'rule of three' for fragment-based lead discovery? , 2003, Drug discovery today.
[15] Yutaka Endo,et al. Development of a Method for Evaluating Drug-Likeness and Ease of Synthesis Using a Data Set in Which Compounds Are Assigned Scores Based on Chemists' Intuition , 2003, J. Chem. Inf. Comput. Sci..
[16] P. Leeson,et al. A comparison of physiochemical property profiles of development and marketed oral drugs. , 2003, Journal of medicinal chemistry.
[17] Michael S Lajiness,et al. Assessment of the consistency of medicinal chemists in reviewing sets of compounds. , 2004, Journal of medicinal chemistry.
[18] R. Abagyan,et al. Comprehensive identification of "druggable" protein ligand binding sites. , 2004, Genome informatics. International Conference on Genome Informatics.
[19] Bruno Boulanger,et al. A Fast Exchange Algorithm for Designing Focused Libraries in Lead Optimization. , 2005 .
[20] J. Proudfoot,et al. The evolution of synthetic oral drug properties. , 2005, Bioorganic & medicinal chemistry letters.
[21] John P. Overington,et al. How many drug targets are there? , 2006, Nature Reviews Drug Discovery.
[22] Sang Joon Kim,et al. A Mathematical Theory of Communication , 2006 .
[23] T. Keller,et al. A practical view of 'druggability'. , 2006, Current opinion in chemical biology.
[24] Abhyuday Mandal,et al. Identifying Promising Compounds in Drug Discovery: Genetic Algorithms and Some New Statistical Techniques , 2007, J. Chem. Inf. Model..
[25] P. Leeson,et al. The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.
[26] Cele Abad-Zapatero,et al. A sorcerer's apprentice and The Rule of Five: from rule-of-thumb to commandment and beyond. , 2007, Drug discovery today.
[27] Abhyuday Mandal,et al. Identifying Promising Compounds in Drug Discovery: Genetic Algorithms and Some New Statistical Techniques. , 2007 .
[28] Raimund Mannhold,et al. Molecular Drug Properties: Measurement and Prediction , 2007 .
[29] Daniel R. Caffrey,et al. Structure-based maximal affinity model predicts small-molecule druggability , 2007, Nature Biotechnology.
[30] Daniel James,et al. Lessons Learnt from Assembling Screening Libraries for Drug Discovery for Neglected Diseases , 2007, ChemMedChem.
[31] Reinaldo Molina Ruiz,et al. Desirability-based methods of multiobjective optimization and ranking for global QSAR studies. Filtering safe and potent drug candidates from combinatorial libraries. , 2008, Journal of combinatorial chemistry.
[32] M. Gleeson. Generation of a set of simple, interpretable ADMET rules of thumb. , 2008, Journal of medicinal chemistry.
[33] C. Humblet,et al. Escape from flatland: increasing saturation as an approach to improving clinical success. , 2009, Journal of medicinal chemistry.
[34] T. Ritchie,et al. The impact of aromatic ring count on compound developability--are too many aromatic rings a liability in drug design? , 2009, Drug discovery today.
[35] A. Capasso. Comparison with Naloxone of Two Dynorphin a Analogues with K- and δ-Opioid Antagonist Activity , 2009 .
[36] Thomas A. Halgren,et al. Identifying and Characterizing Binding Sites and Assessing Druggability , 2009, J. Chem. Inf. Model..
[37] Christopher A. Lipinski. Chemist's Role from HTS Retest to Lead , 2009 .
[38] Nigel Greene,et al. Physicochemical drug properties associated with in vivo toxicological outcomes: a review , 2009, Expert opinion on drug metabolism & toxicology.
[39] F. Hosseinzadeh Lotfi,et al. Imprecise Shannon's Entropy and Multi Attribute Decision Making , 2010, Entropy.
[40] John Manchester,et al. Evaluation of pKa Estimation Methods on 211 Druglike Compounds , 2010, J. Chem. Inf. Model..
[41] Stevan W. Djuric,et al. F1000Prime recommendation of Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. , 2010 .
[42] G. V. Paolini,et al. How Desirable Are Your IC50s? , 2010, Journal of biomolecular screening.
[43] Amiram Goldblum,et al. Predicting Oral Druglikeness by Iterative Stochastic Elimination , 2010, J. Chem. Inf. Model..
[44] P. Verhoest,et al. Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes. , 2010, ACS chemical neuroscience.
[45] X. Barril,et al. Understanding and predicting druggability. A high-throughput method for detection of drug binding sites. , 2010, Journal of medicinal chemistry.
[46] Yuichi Nagahara,et al. Are There Differences between Launched Drugs, Clinical Candidates, and Commercially Available Compounds? , 2010, J. Chem. Inf. Model..
[47] P. Verhoest,et al. Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties. , 2010, ACS chemical neuroscience.
[48] Tudor I. Oprea,et al. Understanding drug‐likeness , 2011 .
[49] John P. Overington,et al. Probing the links between in vitro potency, ADMET and physicochemical parameters , 2011, Nature Reviews Drug Discovery.
[50] David S. Wishart,et al. DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs , 2010, Nucleic Acids Res..
[51] Sorel Muresan,et al. Analysis of in vitro bioactivity data extracted from drug discovery literature and patents: Ranking 1654 human protein targets by assayed compounds and molecular scaffolds , 2011, J. Cheminformatics.
[52] Niklas Blomberg,et al. Strategies to improve in vivo toxicology outcomes for basic candidate drug molecules. , 2011, Bioorganic & medicinal chemistry letters.
[53] M. Hann. Molecular obesity, potency and other addictions in drug discovery , 2011 .